Interests
cardiorenal medicine; heart disease; kidney disease; biomarkers; COVID-19
Latest Publications
- Open Access EditorialRole of hydroxychloroquine in multidrug treatment of COVID-19Peter A. McCullough, Raphael B. Stricker, Harvey A. RischRev. Cardiovasc. Med. 2021, 22(3), 545–546; https://doi.org/10.31083/j.rcm2203063539Downloads2364Views
- Open Access EditorialSARS-CoV-2 infection and the COVID-19 pandemic: a call to action for therapy and interventions to resolve the crisis of hospitalization, death, and handle the aftermathPeter A. McCullough, Kris VijayRev. Cardiovasc. Med. 2021, 22(1), 9–10; https://doi.org/10.31083/j.rcm.2021.01.301(This article belongs to the Special Issue Utilizing Technology in the COVID 19 era)152Downloads4Citations622Views
- Open Access News and ViewsEarly multidrug regimens in new potentially fatal medical problemsPeter A. McCullough, Ramin OskouiRev. Cardiovasc. Med. 2020, 21(4), 507–508; https://doi.org/10.31083/j.rcm.2020.04.270(This article belongs to the Special Issue Utilizing Technology in the COVID 19 era)36Downloads1Citations175Views
- Open Access ReviewMultifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19)Peter A. McCullough, Paul E. Alexander, Robin Armstrong, Cristian Arvinte, ... Vladimir ZelenkoRev. Cardiovasc. Med. 2020, 21(4), 517–530; https://doi.org/10.31083/j.rcm.2020.04.264(This article belongs to the Special Issue Utilizing Technology in the COVID 19 era)4191Downloads51Citations19295Views
- Open Access Original ResearchClinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infectionBrian C. Procter, Casey Ross, Vanessa Pickard, Erica Smith, ... Peter A. McCulloughRev. Cardiovasc. Med. 2020, 21(4), 611–614; https://doi.org/10.31083/j.rcm.2020.04.260389Downloads30Citations2364Views
- Open Access News and ViewsUrgent need for individual mobile phone and institutional reporting of at home, hospitalized, and intensive care unit cases of SARS-CoV-2 (COVID-19) infectionPeter A. McCullough, John Eidt, Janani Rangaswami, Edgar Lerma, ... Claudio RoncoRev. Cardiovasc. Med. 2020, 21(1), 1–7; https://doi.org/10.31083/j.rcm.2020.01.4242Downloads18Citations858Views
- Open Access ReviewContrast induced acute kidney injury in interventional cardiology: an update and key guidance for cliniciansFederico Ronco, Giuseppe Tarantini, Peter A. McCulloughRev. Cardiovasc. Med. 2020, 21(1), 9–23; https://doi.org/10.31083/j.rcm.2020.01.44286Downloads14Citations1184Views
- Open Access Treatment UpdateKey updates in Cardio-Nephrology from 2018: springboard to a bright FutureJanani Rangaswami, Sandeep Soman, Peter A. McCulloughRev. Cardiovasc. Med. 2018, 19(4), 113–116; https://doi.org/10.31083/j.rcm.2018.04.896791Downloads1Citations676Views
- Open Access ReviewAlteration of lipid metabolism in chronic kidney disease, the role of novel antihyperlipidemic agents, and future directionsSivakumar Sudhakaran, Teodoro Bottiglieri, Kristen M. Tecson, Aaron Y. Kluger, Peter A. McCulloughRev. Cardiovasc. Med. 2018, 19(3), 77–88; https://doi.org/10.31083/j.rcm.2018.03.9081310Downloads5Citations974Views
- Open Access ReviewInhibition of the Sodium–Proton Antiporter (Exchanger) is a Plausible Mechanism of Potential Benefit and Harm for Drugs Designed to Block Sodium Glucose Co-transporter 2Peter A. McCullough, Aaron Y. Kluger, Kristen M. Tecson, Clay M. Barbin, Andy Y. Lee, ... Janani RangaswamiRev. Cardiovasc. Med. 2018, 19(2), 51–63; https://doi.org/10.31083/j.rcm.2018.02.0213821Downloads6Citations1655Views